Letermovir denied as duplicate or overlapping therapy by Humana?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Letermovir
## Why Humana Denies Letermovir as Duplicate Therapy — and Why It's Appealable
Letermovir is an antiviral agent approved for CMV (cytomegalovirus) prophylaxis in certain transplant recipients. A duplicate-therapy denial from Humana means the plan is asserting that another drug already on claim — typically another antiviral — covers the same clinical purpose and that both agents are not medically necessary simultaneously. This denial type is often based on automated claim-editing logic and frequently does not account for the distinct mechanism of action letermovir has compared to older antivirals, or the specific transplant guideline recommendations that support its use.
## The Federal Legal Framework
All Humana commercial plan appeals are governed by: - ERISA §503 (employer-sponsored plans): requires a full-and-fair review with written denial rationale. - ACA §2719 (individual and fully-insured group plans): guarantees an independent external review if the internal appeal fails, generally available within approximately four months of denial. An expedited process exists when the patient's condition is serious or rapidly progressing.
## Concrete Appeal Steps and Timeline
1. Request the complete denial letter: Humana must identify which drug it considers duplicative and which clinical criterion it is applying. 2. First-level internal appeal: file within the timeframe stated in your denial letter (commonly 180 days). Humana must respond within 30 days for pre-service and 60 days for retrospective appeals. 3. Peer-to-peer review: before or during the appeal, the prescribing physician can request a peer-to-peer call with Humana's medical director to explain the clinical rationale directly. 4. External review: if the internal appeal is denied, request independent external review; use the expedited track for time-sensitive transplant prophylaxis needs.
## Documentation to Gather
- Transplant records: documentation of transplant type, date, donor/recipient serostatus, and immunosuppression regimen, which establish the clinical context for letermovir use.
- CMV risk stratification: chart notes from the transplant infectious disease or transplant team documenting why letermovir is indicated for this patient's specific risk profile.
- Distinction from the other agent: a clinical note or prescriber letter explaining how letermovir's mechanism of action differs from the drug Humana considers duplicative, and why both agents serve distinct clinical roles if applicable.
- Applicable guidelines: reference the relevant transplant society guideline organization (e.g., the applicable AST or AATM guideline) without citing specific numbers — confirm with the current published guideline.
- Prescriber medical-necessity letter: explicit statement that the two agents are not interchangeable and that concurrent or sequential use is consistent with the current standard of care for this patient.
## Criteria-Mapping Structure
Obtain Humana's published coverage policy for letermovir and its duplicate-therapy editing criteria. Build a two-column table: left column lists each element of Humana's duplicate-therapy rule; right column provides the chart fact or clinical explanation that refutes duplication. Key argument: letermovir's distinct mechanism and the published transplant guidelines supporting its use separate it from older antivirals in ways Humana's automated edits may not capture. A prescriber-led peer-to-peer call combined with a thorough written appeal resolves the majority of duplicate-therapy denials in this class.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →